Blocking the interaction between HIV-1 integrase and human LEDGF/p75: mutational studies, virtual screening and...

Area of Science:

• Biochemistry
• Virology
• Computational Biology

Background:

• HIV-1 integrase (IN) is essential for integrating viral DNA into the host genome.
• LEDGF/p75 acts as a co-factor, crucial for HIV-1 IN function and viral replication.
• The IN-LEDGF/p75 interaction is a key target for developing anti-HIV therapeutics.

Purpose of the Study:

• To investigate the IN-LEDGF/p75 interaction using in silico methods.
• To identify potential drug candidates that inhibit this interaction.
• To understand the binding mechanisms and stability of inhibitor-IN complexes.

Main Methods:

• In silico mutational studies and molecular dynamics simulations to analyze the IN-LEDGF/p75 complex.
• Structure-based virtual screening of the ChemBridge database against HIV-1 IN.
• Docking simulations with varying precision and computational intensity.
• Analysis of binding affinity, pharmacokinetic parameters, and molecular dynamics of selected compounds.

Main Results:

• Key residues in the IN-LEDGF/p75 binding pocket are vital for complex stabilization.
• Six promising compounds were identified through virtual screening.
• Molecular dynamics simulations confirmed the stability of these compounds within the IN binding site.
• Specific IN residues (Glu170, His171, Thr174, Gln95, Thr125) were found to be critical for compound binding.

Conclusions:

• The identified compounds effectively target the IN-LEDGF/p75 interaction.
• These findings provide a potential strategy for developing novel anti-HIV drugs.
• This approach may help overcome viral resistance and cross-resistance issues.